COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN

被引：1
|
作者：
Shibahara, H. [1 ]
Shiroiwa, T. [2 ]
Nakamura, K. [1 ]
Shimozuma, K. [1 ]
机构：
[1] Ritsumeikan Univ, Kusatsu, Japan
[2] Natl Inst Publ Hlth, Saitama, Japan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.532
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A415 / A416
页数：2
相关论文
共 50 条
  • [31] EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE
    Villa, J. C.
    Espinosa, J.
    Gomez, R.
    Sanchez, V
    Lopez, R.
    Galan, R.
    Pineda, M. D.
    Perez, M.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A817
  • [32] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [33] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [34] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [35] Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Hutson, Thomas E.
    Vogelzang, Nicholas J.
    Sonpavde, Guru
    FUTURE ONCOLOGY, 2010, 6 (05) : 665 - 679
  • [36] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Goudarzi, Zahra
    Lotfi, Farhad
    Najafpour, Zhila
    Hafezi, Aliakbar
    Zakaria, Marzieh Alizadeh
    Keshavarz, Khosro
    BMC UROLOGY, 2024, 24 (01)
  • [38] Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
    Rauch, Simon
    Fong, Dominic
    Morra, Elisa
    Maines, Francesca
    Caffo, Orazio
    Spizzo, Gilbert
    PROSTATE INTERNATIONAL, 2016, 4 (02) : 54 - 55
  • [39] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Zahra Goudarzi
    Farhad Lotfi
    Zhila Najafpour
    AliAkbar Hafezi
    Marzieh Alizadeh Zakaria
    Khosro Keshavarz
    BMC Urology, 24
  • [40] Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Zobniw, Chrystia M.
    Causebrook, Alanna
    Fong, Mei Ka
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 97 - 105
12345